Characteristics of FVIII ITI regimens used
| . | Low dose nondaily . | Low dose daily . | High dose nondaily . | High dose daily . |
|---|---|---|---|---|
| Number (%) or median (P25-P75) | ||||
| Treatment | ||||
| Treatment courses | 49 | 5 | 48 | 181 |
| Duration, y | 0.81 (0.52-1.45) | 0.67 (0.42-1.60) | 0.99 (0.63-1.32) | 0.85 (0.48-1.40) |
| Maximum inhibitor titer (BU) | 39 (7-284) | 8 (4-547) | 76 (13-622) | 83 (16-276) |
| Infusions per week, n | 3.0 (3.0-3.1) | 7.0 (7.0-7.0) | 3.5 (3.0-3.5) | 7.0 (7.0-14.0) |
| FVIII dose/kg per week | 176 (150-218) | 500 (369-560) | 401 (350-499) | 1400 (1050-2545) |
| Bleeding | ||||
| ABR (mean, 95% CI) | 5.67 (3.96-8.12) | 2.46 (0.80-7.53) | 6.70 (4.69-9.56) | 3.20 (2.62-3.89) |
| AJBR (mean, 95% CI) | 2.48 (1.66-3.70) | 0.45 (0.08-2.42) | 2.98 (2.02-4.39) | 1.21 (0.97-1.51) |
| . | Low dose nondaily . | Low dose daily . | High dose nondaily . | High dose daily . |
|---|---|---|---|---|
| Number (%) or median (P25-P75) | ||||
| Treatment | ||||
| Treatment courses | 49 | 5 | 48 | 181 |
| Duration, y | 0.81 (0.52-1.45) | 0.67 (0.42-1.60) | 0.99 (0.63-1.32) | 0.85 (0.48-1.40) |
| Maximum inhibitor titer (BU) | 39 (7-284) | 8 (4-547) | 76 (13-622) | 83 (16-276) |
| Infusions per week, n | 3.0 (3.0-3.1) | 7.0 (7.0-7.0) | 3.5 (3.0-3.5) | 7.0 (7.0-14.0) |
| FVIII dose/kg per week | 176 (150-218) | 500 (369-560) | 401 (350-499) | 1400 (1050-2545) |
| Bleeding | ||||
| ABR (mean, 95% CI) | 5.67 (3.96-8.12) | 2.46 (0.80-7.53) | 6.70 (4.69-9.56) | 3.20 (2.62-3.89) |
| AJBR (mean, 95% CI) | 2.48 (1.66-3.70) | 0.45 (0.08-2.42) | 2.98 (2.02-4.39) | 1.21 (0.97-1.51) |